Details of the Drug Combinations

General Information of This Drug (ID: DM28D05)

Drug Name

Oritavancin DM28D05

Synonyms

Nuvocid; Oritavancin [INN]; LY333328; Chlorobiphenyl-chloroeremomycin; (3S,6R,7R,22R,23S,26S,36R,38aR)-22-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-mannopyranosyloxy)-3-(carbamoylmethyl)-10,19-dichloro-44-[2-O-[3-(4'-chlorobiphenyl-4-ylmethylamino)-2,3,6-trideoxy-3-C-me; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3''-(4'-chloro[1,1'-biphenyl]-4-ylmethyl)vancomycin; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]
Gram-positive bacterial infection	1B74-1G40	Terminated	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Oritavancin + Warfarin	DCCXVOI	Warfarin	Acute Bacterial Skin and Skin Structure Infection	[3]
------------------------------------------------------------------------------------

References

1	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
2	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
3	ClinicalTrials.gov (NCT02452918) A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)